X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Divis Laboratories with PLETHICO PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs PLETHICO PHARMA - Comparison Results

DIVIS LABORATORIES    Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES PLETHICO PHARMA DIVIS LABORATORIES/
PLETHICO PHARMA
 
P/E (TTM) x 32.5 -1.1 - View Chart
P/BV x 5.8 0.0 34,676.1% View Chart
Dividend Yield % 0.9 0.0 -  

Financials

 DIVIS LABORATORIES   PLETHICO PHARMA
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-17
PLETHICO PHARMA
Mar-14
DIVIS LABORATORIES/
PLETHICO PHARMA
5-Yr Chart
Click to enlarge
High Rs1,222395 309.4%   
Low Rs78431 2,504.8%   
Sales per share (Unadj.) Rs153.1604.4 25.3%  
Earnings per share (Unadj.) Rs39.932.5 123.0%  
Cash flow per share (Unadj.) Rs44.651.3 86.9%  
Dividends per share (Unadj.) Rs10.000-  
Dividend yield (eoy) %1.00-  
Book value per share (Unadj.) Rs201.8473.6 42.6%  
Shares outstanding (eoy) m265.4734.08 779.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x6.60.4 1,858.1%   
Avg P/E ratio x25.16.6 382.7%  
P/CF ratio (eoy) x22.54.2 541.8%  
Price / Book Value ratio x5.00.5 1,104.4%  
Dividend payout %25.00-   
Avg Mkt Cap Rs m266,2667,262 3,666.3%   
No. of employees `0009.7NA-   
Total wages/salary Rs m4,6871,596 293.7%   
Avg. sales/employee Rs Th4,175.0NM-  
Avg. wages/employee Rs Th481.5NM-  
Avg. net profit/employee Rs Th1,089.3NM-  
INCOME DATA
Net Sales Rs m40,64320,598 197.3%  
Other income Rs m749386 193.8%   
Total revenues Rs m41,39220,984 197.3%   
Gross profit Rs m14,4602,818 513.2%  
Depreciation Rs m1,233642 192.0%   
Interest Rs m231,593 1.4%   
Profit before tax Rs m13,953969 1,440.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,349-138 -2,420.3%   
Profit after tax Rs m10,6041,107 958.0%  
Gross profit margin %35.613.7 260.1%  
Effective tax rate %24.0-14.3 -168.0%   
Net profit margin %26.15.4 485.5%  
BALANCE SHEET DATA
Current assets Rs m40,10518,877 212.5%   
Current liabilities Rs m6,59511,896 55.4%   
Net working cap to sales %82.533.9 243.3%  
Current ratio x6.11.6 383.3%  
Inventory Days Days11936 329.9%  
Debtors Days Days81198 40.8%  
Net fixed assets Rs m19,9959,861 202.8%   
Share capital Rs m531341 155.8%   
"Free" reserves Rs m53,04312,331 430.2%   
Net worth Rs m53,57416,139 332.0%   
Long term debt Rs m04,706 0.0%   
Total assets Rs m61,58533,146 185.8%  
Interest coverage x618.41.6 38,460.6%   
Debt to equity ratio x00.3 0.0%  
Sales to assets ratio x0.70.6 106.2%   
Return on assets %17.38.1 211.8%  
Return on equity %19.86.9 288.6%  
Return on capital %26.112.3 212.3%  
Exports to sales %021.4 0.0%   
Imports to sales %25.215.2 165.8%   
Exports (fob) Rs mNA4,402 0.0%   
Imports (cif) Rs m10,2593,136 327.2%   
Fx inflow Rs m35,3844,402 803.7%   
Fx outflow Rs m10,3993,184 326.6%   
Net fx Rs m24,9851,219 2,050.5%   
CASH FLOW
From Operations Rs m11,4932,437 471.5%  
From Investments Rs m-11,372-6,265 181.5%  
From Financial Activity Rs m-932,490 -3.7%  
Net Cashflow Rs m28-1,337 -2.1%  

Share Holding

Indian Promoters % 52.0 82.7 62.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.8 4.3 274.4%  
FIIs % 19.0 5.5 345.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.2 7.5 229.3%  
Shareholders   31,796 10,665 298.1%  
Pledged promoter(s) holding % 0.0 85.7 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   VENUS REMEDIES  ORCHID PHARMA LTD  PFIZER  J.B.CHEMICALS  SHASUN PHARMA  

Compare DIVIS LABORATORIES With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 284 Points Up; FMCG & Metal Stocks Top Gainers(Closing)

Indian share markets settled higher today taking cues from their Asian peers. At the closing bell, BSE Sensex ended up by 284 points.

Related Views on News

DIVIS LABORATORIES Announces Quarterly Results (1QFY19); Net Profit Up 50.8% (Quarterly Result Update)

Aug 6, 2018 | Updated on Aug 6, 2018

For the quarter ended June 2018, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 50.8% YoY). Sales on the other hand came in at Rs 10 bn (up 21.2% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (4QFY18); Net Profit Up 0.9% (Quarterly Result Update)

May 28, 2018 | Updated on May 28, 2018

For the quarter ended March 2018, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 0.9% YoY). Sales on the other hand came in at Rs 11 bn (up 2.0% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

This is a Must-Have Stock for Your Portfolio(The 5 Minute Wrapup)

Aug 8, 2018

Tanushree just released the permanent wealth blueprint report. This report includes three safe and steady stocks. I like one in particular. Here's why

Trading in These Times: 8% Gains in 3 Days!(Profit Hunter)

Aug 9, 2018

Here are 2 stocks you can buy right now! And there are plenty more opportunities to come...

Only on WhatsApp, a Weaker Rupee Means a Weaker India(Vivek Kaul's Diary)

Aug 16, 2018

While dollar crossing Rs 70 will have its repercussions, the world isn't exactly coming to an end.

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

HDFC AMC Makes 65% Listing Gains! Should It Attract Mutual Fund Investors?(Outside View)

Aug 8, 2018

PersonalFN explains if investors should invest in schemes of HDFC Mutual Fund looking at the listing gains of HDFC AMC.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Aug 17, 2018 (Close)

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES - DR. REDDYS LAB COMPARISON

COMPARE DIVIS LABORATORIES WITH

MARKET STATS